balance equationreview2022-09-30
Difference 158779000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$284.00K
Fiscal year ended 2025-12-31Operating income
-$69.54M
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $284.00K and net income of -$64.43M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Dianthus Therapeutics, Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $284.00K | $396.00K | $193.00K | $1.16M | $1.33M | $2.17M | $1.86M | $874.00K | $457.00K | $924.00K |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$69.54M | -$40.29M | -$34.93M | -$33.18M | -$31.92M | -$29.90M | -$22.20M | -$17.84M | -$12.96M | -$15.76M |
| Net income | -$64.43M | -$36.76M | -$31.63M | -$29.51M | -$28.44M | -$25.17M | -$17.61M | -$13.75M | -$10.56M | -$14.76M |
| Research & development | $59.90M | $32.49M | $26.25M | $27.00M | $26.41M | $25.54M | $18.07M | $13.08M | $8.78M | $7.96M |
| Weighted-average diluted shares | Unavailable | shares 37.79M | shares 35.82M | shares 35.79M | Unavailable | shares 34.24M | shares 34.23M | shares 25.67M | Unavailable | shares 3.91M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | Unavailable | $-0.97 | $-0.88 | $-0.82 | Unavailable | $-0.74 | $-0.51 | $-0.54 | Unavailable | $-3.78 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $9.93M | $8.20M | $8.87M | $7.34M | $6.83M | $6.53M | $6.00M | $5.64M | $4.63M | $8.72M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.09M | $55.98M | $13.24M | $10.12M | $22.79M | $33.67M | $314.17M | $329.72M | $132.32M | $157.28M |
| Total assets | $530.92M | $577.44M | $326.08M | $348.58M | $374.01M | $354.25M | $368.96M | $382.46M | $179.40M | $192.46M |
| Current assets | $409.44M | $413.82M | $263.60M | $271.00M | $280.90M | $287.49M | $365.69M | $380.93M | $177.45M | $191.45M |
| Total liabilities | $37.52M | $30.99M | $23.00M | $19.97M | $21.53M | $16.35M | $10.74M | $9.78M | $10.54M | $14.08M |
| Current liabilities | $30.73M | $23.86M | $20.09M | $16.95M | $18.45M | $15.71M | $10.03M | $8.96M | $9.63M | $13.08M |
| Total equity incl. NCI | $493.40M | $546.45M | $303.08M | $328.61M | $352.48M | $337.90M | $358.22M | $372.69M | $168.87M | $178.38M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $0 | $0 |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $52.00K | $5.00M | $39.00K | $1.00M | $0 | $1.39M | $840.00K | $435.00K | $294.00K | $232.00K |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $9.72M | $6.70M | $5.40M | $8.27M | $4.58M | $7.57M | $3.70M | $2.61M | $2.61M | $1.37M |
Cash flow
| Metric | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.98M | -$30.56M | -$23.89M | -$27.63M | -$27.44M | -$21.27M | -$14.53M | -$14.94M | -$11.85M | Unavailable |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | $37.20M | -$201.28M | $26.44M | $14.79M | -$23.11M | -$259.36M | $1.17M | -$5.51M | -$8.24M | Unavailable |
| Financing cash flow | $4.88M | $274.51M | $568.00K | $161.00K | $39.68M | $296.00K | -$2.20M | $217.85M | -$4.86M | Unavailable |
| Net change in cash | -$4.90M | $42.68M | $3.12M | -$12.68M | -$10.88M | -$280.34M | -$15.56M | $197.40M | -$24.96M | Unavailable |
| Stock-based compensation | $5.98M | $5.79M | $5.71M | $5.32M | $3.92M | $3.84M | $3.10M | $2.04M | $726.00K | Unavailable |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | -24486.3% | -10173.7% | Unavailable | Unavailable | -2406.9% | -1376.6% | -1191.8% | -2041.6% | -2835.0% | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 2104.9% | 1463.1% | Unavailable | Unavailable | 295.5% | 176.8% | 166.5% | 232.8% | 158.9% | Unavailable |
| Current ratio | 13.32x | 17.35x | 13.12x | 15.99x | 15.22x | 18.30x | 36.46x | 42.52x | 18.42x | 14.64x |
| Revenue YoY growth | -78.6% | -81.8% | -89.6% | 33.1% | 190.2% | 135.1% | Unavailable | Unavailable | Unavailable | -21.2% |
| Net margin | -22687.3% | -9284.1% | Unavailable | Unavailable | -2144.8% | -1159.0% | Unavailable | Unavailable | -2311.4% | Unavailable |
| R&D / revenue | 21089.8% | 8204.3% | Unavailable | Unavailable | 1991.9% | 1176.1% | 969.9% | 1496.3% | 1921.4% | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DNTH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.